Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 27
2017 4
2019 1
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C. Pereira B, et al. Nat Commun. 2016 May 10;7:11479. doi: 10.1038/ncomms11479. Nat Commun. 2016. PMID: 27161491 Free PMC article.
With one eye on the future.
Caldas C, Rescigno M, Turajlic S, Madabhushi A, Zhang Z, Lito P, Brown CE, Pantel K, Haanen J, Duma N. Caldas C, et al. Cancer Cell. 2022 Mar 14;40(3):221-225. doi: 10.1016/j.ccell.2022.02.019. Cancer Cell. 2022. PMID: 35290781 Free article.
Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Byrne AT, et al. Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Nat Rev Cancer. 2017. PMID: 28104906 Free article. Review.
Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.
Rajan A, Berns A, Ringborg U, Celis J, Ponder B, Caldas C, Livingston D, Bristow RG, Hecht TT, Tursz T, van Luenen H, Bono P, Helander T, Seamon K, Smyth JF, Louvard D, Eggermont A, van Harten WH. Rajan A, et al. Mol Oncol. 2016 May;10(5):645-51. doi: 10.1016/j.molonc.2015.12.007. Epub 2015 Dec 23. Mol Oncol. 2016. PMID: 26797050 Free PMC article. Review.
Stratification and therapeutic potential of PML in metastatic breast cancer.
Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L, Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, Garcia S, Macías I, Salvador F, Domenici G, Rueda OM, Zabala-Letona A, Arruabarrena-Aristorena A, Zúñiga-García P, Caro-Maldonado A, Valcárcel-Jiménez L, Sánchez-Mosquera P, Varela-Rey M, Martínez-Chantar ML, Anguita J, Ibrahim YH, Scaltriti M, Lawrie CH, Aransay AM, Iovanna JL, Baselga J, Caldas C, Barrio R, Serra V, Vivanco Md, Matheu A, Gomis RR, Carracedo A. Martín-Martín N, et al. Nat Commun. 2016 Aug 24;7:12595. doi: 10.1038/ncomms12595. Nat Commun. 2016. PMID: 27553708 Free PMC article.
Subtype-specific micro-RNA expression signatures in breast cancer progression.
Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, Lüders T, Chin SF, Git A, Caldas C, Kristensen VN, Brazma A, Børresen-Dale AL, Hovig E, Helland Å. Haakensen VD, et al. Int J Cancer. 2016 Sep 1;139(5):1117-28. doi: 10.1002/ijc.30142. Epub 2016 May 9. Int J Cancer. 2016. PMID: 27082076
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. Earl HM, et al. Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178152 Free PMC article. Clinical Trial.
SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.
Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT. Abdel-Fatah TMA, et al. Lancet Oncol. 2016 Jul;17(7):1004-1018. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14. Lancet Oncol. 2016. PMID: 27312051 Clinical Trial.
30 results